The Complete Guide to Using AI in the Healthcare Industry in Argentina in 2025

Argentina's healthcare AI market is moving from pilot projects to real-scale opportunity: revenue jumped from about USD 35.5 million in 2023 and is forecast to surge to roughly USD 304.8 million by 2030 (a near ninefold leap at a 36% CAGR), while the payer segment alone is projected at about US$61.7 million by 2030 - signals that hospitals, insurers, and startups should pay attention to imaging, telemedicine and precision‑medicine use cases already rising across Latin America.

For anyone in clinical, product, or policy roles, this is a practical moment to build AI capability; explore the Argentina AI in Healthcare market research for the numbers and trends and consider skill-building like the AI Essentials for Work bootcamp syllabus (15-week) to learn promptcraft and workplace AI tools.

A fast, skills-first approach will turn wide-open market forecasts into real projects that speed diagnosis and reduce costs for Argentine patients.

Metric	Value
Argentina AI in Healthcare (2023)	USD 35.5 million
Argentina AI in Healthcare (2030 forecast)	USD 304.8 million
CAGR (2024–2030)	36%
Argentina AI for Healthcare Payer (2030)	US$ 61.7 million
Latin America AI in Healthcare (2024)	USD 0.47 billion

Understanding Argentina's regulatory framework for AI in healthcare means seeing rules as a layered system rather than one single AI law: the Ministry of Health drives telemedicine and electronic prescriptions (Decree 98/23 and the ReNaPDiS registry), ANMAT enforces medical device and SaMD safety (recently updated by provisions including ANMAT 64/2025 and Regulation 9,688/19), and the Access to Public Information Agency (AAIP) polices data protection and AI guidance under Law 25,326 and Resolution 161/2023 - with non‑binding ethics recommendations (Provision 2/2023) and draft bills proposing further AI-specific rules.

Practically, many AI tools will be assessed first as medical devices/SaMD (so plan for device classification, clinical validation and possible local clinical trials), while data‑handling must meet the Data Protection Regime's transparency, consent and cross‑border safeguards; provinces can layer on their own requirements, so prepare for federal and provincial checkpoints.

Treat AI models as dual‑risk projects - both a software engineering challenge and a regulated health product - and remember the regulator's mindset: ANMAT's four risk classes (I–IV) are the ladder that will determine documentation, trials and timelines, so map your product early to avoid surprises.

For concise legal guidance see the ICLG chapter on Argentina's digital health laws and ANMAT's overview of its role and device rules.

Authority	Primary Role in AI/Healthcare
Ministry of Health (MoH)	Telemedicine/e‑prescription policy, ReNaPDiS registry
ANMAT	Regulates medical devices/SaMD, classification (Class I–IV), clinical/market approvals
AAIP	Data protection enforcement, AI transparency programs and guidance
Provincial authorities	Local health rules and licensing that may supplement federal regulation

In Argentina, many AI-powered tools cross the line from helpful software into regulated medical products when their intended purpose is clinical - ANMAT treats standalone programs, mobile apps and even software that analyses specimens as Software as a Medical Device (SaMD), so expect registration, risk‑based classification and evidence requirements before market entry; see ANMAT's role and remit for device oversight and the recent SaMD updates summarized in the ICLG Argentina chapter and ANMAT materials (ICLG Argentina digital health laws and regulations 2025 overview, ANMAT device oversight and remit: What is ANMAT?).

Practical triggers for SaMD include software intended for diagnosis, monitoring, treatment or in‑vitro analysis (mobile apps that turn a phone into a diagnostic aid or tools that output clinical decisions can be regulated), and in vitro diagnostic software follows the updated registration rules in Disposition 2198/2022 (Allende amendments to the in vitro diagnostic regulatory framework 2198/2022 summary).

The real takeaway: map your AI's intended use to ANMAT's SaMD definition early, classify the risk class (I–IV) and budget time for clinical validation - after all, even a seemingly simple app that flags an abnormal result can move from cool prototype to fully regulated medical device overnight.

AI tool type	When it counts as SaMD / medical device
Mobile apps	If intended for diagnosis, monitoring, treatment or in‑vitro analysis (may require SaMD registration)
Standalone software / cloud models	When the main action is medical (not merely administrative); register per ANMAT rules and risk class
Clinical decision support	May be SaMD if it provides recommendations that could affect clinical outcomes

SaMD is defined as software or related product intended to be used for specific medical purposes, where main action is not pharmacological/immunological/metabolic, including:

Data protection is a core regulatory axis for any AI health project in Argentina: the Personal Data Protection Law (Law 25,326) still sets the baseline for collecting, storing and correcting patient data, while the Agency for Access to Public Information (AAIP) enforces registration and transparency rules that can directly affect model training and deployment - every archive, registry or databank must be registered with details such as purpose, retention periods and security measures, so plan to document access logs and retention policies from day one.

Health and genetic data are treated as sensitive and need stronger safeguards and usually express consent or lawful justification; transfers abroad are tightly controlled (only to “adequate” jurisdictions or under narrow exceptions), so cloud-hosting and cross‑border pipelines must be mapped against these limits.

Argentina is actively modernizing its regime: a Draft Law circulated in 2024–25 would bring GDPR‑style features - extraterritorial scope, new rights (portability, objection), mandatory impact assessments and a 72‑hour breach notification rule - meaning compliance is moving from optional hygiene to a project‑level requirement (Draft Law overview for Argentina data protection reform).

For a concise legal grounding and the current statutory text, review Argentina's Personal Data Protection Law (PDPL) summary and the Draft Law analysis and implications for healthcare AI to align consent flows, DPIAs and registry filings with both present rules and imminent changes.

Requirement	Practical effect for AI in healthcare
Law 25,326 (PDPL)	Baseline rules on consent, accuracy, purpose limitation and rights of access/rectification (Argentina Personal Data Protection Law (Law 25,326) overview)
Enforcement authority	AAIP: registry administration, inspections and sanctions
Registration	All databases must be registered with purpose, retention and security details
Sensitive data	Health/genetic data require stronger protections and usually express consent
Cross‑border transfers	Allowed to “adequate” countries or with specific legal exceptions; extra caution for cloud/third‑party ML providers
Security & breach rules	Technical/organizational measures required; current law lacks a general 72‑hour rule but the Draft Law proposes mandatory breach notification

Bringing an AI health tool to Argentine patients means treating validation and ANMAT approval as essential milestones, not optional paperwork: ANMAT uses a four‑class risk scale (Class I–IV) that drives whether you need pre‑market clinical trials, the depth of technical documentation and the timeline for clearance, so map your intended medical purpose to risk class early and appoint a local authorized representative before filing.

For devices that require trials, Provision 969/97 sets out the trial dossier and an initial administrative decision window (about 90 business days, subject to pauses for deficiencies), while more complex Class III–IV submissions demand full technical reports, original safety/effectiveness tests and a longer review - expect Class III/IV reviews of roughly 60–120 working days and a typical end‑to‑end registration path of about 12–15 months.

Post‑market duties are real: ANMAT now enforces continuous technovigilance (Provision 8194/2023), Spanish labeling, and five‑year registration revalidation, so plan risk‑management, adverse‑event reporting and supply/import logistics up front to avoid costly delays at customs.

For practical guidance on documentation and timelines see the ANMAT overview and the Artixio summary of Argentina's device rules, which list required trial documents, dossier checklists and fee ranges that will shape your go/no‑go decisions.

Item	Typical detail
Risk classification	Class I–IV (ANMAT, risk‑based)
Clinical trial decision	~90 business days (subject to suspensions) per Provision 969/97
Review times	Class I/II: ~15–30 working days; Class III/IV: ~60–120 working days
End‑to‑end registration	Typically 12–15 months
Registration validity	5 years; revalidation required before expiry
Example fees (approx., USD)	Class I $155 · Class II $195 · Class III $260 · Class IV $360

Deploying AI in Argentina's telemedicine and e‑prescription ecosystem means designing for a tightly regulated, safety‑first workflow: electronic prescriptions became mandatory on July 1, 2024 and platforms that issue prescriptions, store digital formularies or host telecare systems must register with the Ministry of Health's ReNaPDiS and follow the rules in Decree 98/23 and related MoH regulations - so map your integration, authentication and audit trails early (Argentina Decree 98/23, ReNaPDiS and electronic prescription regulatory requirements).

Teleconsultations must meet practical quality standards (private, soundproof, well‑lit spaces; access to prior clinical data; clear informed consent) and platforms are required to protect credentials, host servers securely in approved environments, ensure interoperability with national systems and provide fallback channels if a connection drops - plan for those operational details from day one (Argentina teleconsultation good-practice guidelines and platform obligations).

Importantly, current guidance treats AI in telemedicine as a supervised decision‑support tool rather than an autonomous clinician: keep humans in the loop, document model outputs, log rationale for clinical use and ensure compliance with data‑protection and patient‑rights rules when training, deploying or updating models in the field.

Data governance in Argentina is a compliance-first design choice: health projects must align with the Personal Data Protection Law (Law 25,326) and AAIP rules, register any patient databank, and treat health and genetic records as sensitive - meaning express consent, strong security and documented retention policies are essential steps before model training or cloud migration.

Cross‑border transfers are tightly controlled (allowed only to “adequate” jurisdictions or via SCCs/BCRs), Decree 98/23 requires that recipients of transferred data meet the same obligations as originators, and draft reforms being debated would add GDPR‑style elements such as DPIAs, portability, and a 72‑hour breach notification rule - so build impact assessments and breach playbooks now.

For hosting, public systems have opted for on‑premise, ARSAT datacenters and containerized platforms (the Ministry of Health's Red Hat case study shows an ARSAT/OpenShift deployment that scaled through a 1,500% spike in transactions), while private projects using cloud providers must ensure encryption, tight access controls and clear data‑processing agreements with local processors.

Practical governance moves: register with AAIP early, put contracts and SCCs in place for foreign cloud vendors, log access and model lineage, and treat Decree 98/23 ReNaPDiS obligations as part of your deployment checklist (especially for telemedicine and e‑prescription platforms); for a compact regulatory map see the ICLG Argentina digital‑health chapter and a data‑transfer snapshot in the DPA Digital Digest.

Requirement	Practical effect
AAIP database registration	Must register purpose, retention, security; mandatory for patient databanks
Cross‑border transfers	Allowed to “adequate” countries or via SCCs/BCRs; Decree 98/23 adds originator/recipient parity
Sensitive health data	Express consent or legal basis; stricter safeguards and minimisation
Hosting options	On‑premise (ARSAT) common for public sector; cloud allowed with encryption, contracts and local processor appointing
Breach & DPIA expectations	Draft law proposes DPIAs and 72‑hour breach notifications - build processes now
ReNaPDiS / telemedicine	Platforms issuing e‑prescriptions or telecare must register and meet MoH operational and security rules

For AI startups selling into Argentine healthcare, the liability picture is shaped less by an AI‑specific statute and more by robust consumer‑protection and product‑liability rules that already carry real teeth: suppliers, manufacturers and importers can be jointly and severally liable under the Consumer Protection Law and the Civil & Commercial Code, remedies range from repair/replacement and rescission to compensatory and moral damages, and regulators can order recalls or levy administrative fines - so a single clinical safety incident can trigger a recall plus a multi‑year enforcement process.

At the same time, the AAIP and other authorities have layered non‑binding ethical guidance (Provision 2/2023) and a transparency/data‑protection program (Resolution 161/2023) onto projects that use automated decision‑making, and congressional drafts would expand data‑rights and algorithmic transparency; in short, expect scrutiny on explainability, human oversight and data handling.

Practically: map your product claims to consumer‑law obligations, document safety and consent carefully, and design human‑in‑the‑loop controls and clear T&Cs to reduce exposure - Argentina's current regime rewards transparency and punishes surprises.

For a detailed legal roadmap see Argentina's consumer protection overview and a concise survey of the country's AI regulatory advances.

Issue	Practical effect for AI startups
Applicable law	Consumer Protection Law No. 24240, Civil & Commercial Code; PDPL and AAIP guidance
Liability	Joint and several liability across manufacturers/importers/suppliers
Remedies & enforcement	Repair/replace/rescission, damages, recalls, administrative fines; possible criminal liability for fraud
Timelines	Investigations commonly 1–3 years; 3‑year statute of limitations for liability claims
AI‑specific status	No dedicated AI liability statute yet; AAIP recommendations (Provision 2/2023) and transparency program (Resolution 161/2023) signal higher expectations

Argentina consumer protection law and remedies - ICLG: ICLG Argentina consumer protection law and remedies | Regulating Artificial Intelligence in Argentina - WSC Legal: WSC Legal guide to regulating artificial intelligence in Argentina

Building trustworthy health AI in Argentina means turning soft ethics into hard project habits: follow AAIP guidance on transparency and data protection, embed human oversight at every decision point, and treat explainability, bias audits and documented training data as deliverables rather than optional notes.

Practical measures drawn from Argentina's evolving playbook include running DPIAs or impact assessments for high‑risk tools, registering patient databanks with the AAIP and limiting automated decisions where consent or clinical safety requires a human in the loop; these steps echo the country's non‑binding “Recommendations for Reliable AI” and the AAIP Program for Transparency and Data Protection.

Map governance to risk: if the model advises clinical care, align processes with ANMAT/SaMD expectations (clinical validation, versioning, technovigilance); for novel pilots consider regulatory sandboxes and clear contractual terms on data use to enable safe experimentation.

Remember the memorable test: if an algorithm's wrong call could mean a patient misses treatment, design the workflow so a clinician - not code - signs off every time.

Ready to build AI for Argentine healthcare? Start with a short checklist: first, map your product against ANMAT's SaMD criteria so you know whether device rules apply (classification, clinical validation and a local authorised representative are often mandatory) - see the Argentina digital health laws and regulations (ICLG 2025) for the device and regulatory roadmap (Argentina digital health laws and regulations (ICLG 2025)); next, if the project touches telemedicine or e‑prescriptions, design integrations and register with ReNaPDiS under Decree 98/23 so platforms meet MoH operational and security rules (ReNaPDiS telemedicine guidance (IBA)); protect patient data from day one by registering databanks with the AAIP, running DPIAs, and planning lawful cross‑border safeguards under Law 25,326; bake human‑in‑the‑loop controls and rigorous clinical validation into pilots (remember the practical test: if an algorithm's wrong call could mean a patient misses treatment, make a clinician - not code - sign off); and close the skills gap quickly with a focused program such as the AI Essentials for Work 15‑week syllabus - Nucamp (AI Essentials for Work 15-week syllabus - Nucamp).

Start small, document everything, and treat regulation as part of product design so prototypes survive the jump to real patients.

Immediate next step	Why / Regulatory basis
Map product to SaMD and ANMAT classes	Determines clinical evidence, trials and registration (ANMAT/ICLG)
Register telemedicine/e‑prescription platforms in ReNaPDiS	MoH Decree 98/23 requires registration and operational/security controls (telemedicine guidance)
Register databanks with AAIP and run DPIAs	Law 25,326 / AAIP rules govern sensitive health data, consent and cross‑border transfers
Build human‑in‑the‑loop & clinical validation plan	Reduces liability and aligns with ANMAT SaMD expectations
Close skills gaps with targeted training	Practical AI, promptcraft and product workflows speed safe deployment (Nucamp syllabus)